This content is machine translated Small cell lung carcinoma Durvalumab approved as first immunotherapy for patients with LS-SCLC Durvalumab has been approved as a monotherapy in Switzerland for the treatment of adult patients with unresectable small cell lung cancer (LS-SCLC, limited-stage small cell lung cancer) whose disease has...…
View Post 2 min This content is machine translated SCLC Small cell lung cancer in everyday therapy – an update Small cell lung carcinomas must be treated quickly – they usually grow rapidly and form metastases early on. The diagnosis is therefore often only made at an advanced stage. Lung…
View Post 5 min This content is machine translated News from the lung cancer pipeline First targeted substance in KRAS mutation and bispecific immunotherapy While targeted therapies in non-small cell lung cancer (NSCLC) have been on the rise for years, such an option for KRAS-mutatedtumors has been lacking. The small molecule inhibitor Sotorasib, which…
View Post 5 min This content is machine translated Small cell and non-small cell lung cancer Rapid progress through immunotherapy and immunochemotherapy Immunotherapy is one of the milestones of cancer therapy. However, the selection of particularly suitable patients remains a major challenge for first-line use.
View Post 5 min This content is machine translated European Lung Cancer Conference in Geneva Therapy of small cell lung tumors – focus on neutropenia Update on the use of granulocyte colony stimulating factor (G-CSF) in concurrent chemoradiotherapy. Administration in patients with small cell lung cancer may be safer than previously thought.
